Luye Pharma s independently developed drug LY01005 has entered phase III clinical trials for prostate cancer ...
Luye Pharma’s core CNS products, ‘Rivastigmine Transdermal Patches’, have been completed and approved by th...
On June 22nd in Hong Kong, Luye Pharma Group hosted a conference to unveil their Global Collaboration Strategy...
Luye Medical Group announced that it has recently completed a majority equity investment in Novena Heart Centr...
Luye Pharma’s new drug LY03003 has been submitted to the PMDA in Japan for clinical trials approval
Luye Pharma has entered the final stage of New Drug Application (NDA) submissions for the innovative drug LY03...
TOP